Skip to main content

Advertisement

SpringerLink
Log in

Isolated Limb Infusion in a Series of Over 100 Infusions: A Single-Center Experience

  • Regional Cancer Therapies
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Isolated limb infusion (ILI) is a therapeutic option for patients with recurrent, unresectable extremity malignancies.

Methods

A prospectively collected single-institution database of patients undergoing ILI was analyzed for preoperative, intraoperative, and postoperative parameters and outcomes.

Results

From May 2007 to January 2012, a total of 76 patients successfully underwent initial ILI, and 28 after either previous hyperthermic isolated limb perfusion or ILI. Seventy-nine patients (74 %) had melanoma, 24 (22 %) sarcoma, 3 (3 %) Merkel cell, and 1 (1 %) squamous cell carcinoma. There were 55 (72 %) initial and 22 (79 %) repeat lower extremity (LE) ILIs, and 21 (78 %) initial and 6 (22 %) repeat upper extremity (UE) ILIs. Serologic toxicity, measured by serum creatine kinase (CK), peaked higher and later in LE ILIs, median 620 versus 124 IU/L, and postoperative day 4 versus 2, respectively (P < 0.05). LE ILIs had a longer hospital length of stay (LOS), median 6 versus 5 days (P < 0.0001). A median grade II Wieberdink regional toxicity was observed. Three-month follow-up was available in 94 (90 %). A response (overall response rate, ORR) was seen in 72 % of ILIs performed for melanoma and 58 % for sarcoma. No difference in response was observed between UE versus LE or between initial versus repeat ILIs. Repeat UE ILIs, however, appeared to have an improved ORR than repeat LE ILIs, 83 versus 64 %.

Conclusions

ILI may be successfully performed for cutaneous and soft tissue malignancies. LE ILIs have higher CK levels and slightly longer LOS. Repeat ILIs are not associated with increased toxicity and similar ORR. UE ILIs may have better ORR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238–47.

    Article  PubMed  CAS  Google Scholar 

  2. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008;15:2749–56.

    Article  PubMed  Google Scholar 

  3. Turaga KK, Beasley GM, Kane JM, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg. 2011;146:870–5.

    Article  PubMed  Google Scholar 

  4. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma: a 14-year experience. Ann Surg Oncol. 2008;15:3003–13.

    Article  PubMed  Google Scholar 

  5. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma a reflection of tumor biology. Ann Surg. 2007;245:591–6.

    Article  PubMed  Google Scholar 

  6. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706–17.

    Article  PubMed  Google Scholar 

  7. Beasley GM, Parsons C, Broadwater G, et al. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg. 2012;256:350–6.

    Article  PubMed  Google Scholar 

  8. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol. 2012;19:1637–43.

    Article  PubMed  Google Scholar 

  9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p 325–44.

    Google Scholar 

  10. Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol. 2007;14:1604–11.

    Article  PubMed  Google Scholar 

  11. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–96.

    Article  PubMed  Google Scholar 

  12. Testori A, Verhoef C, Kroon HM, et al. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol. 2011;104:397–404.

    Article  PubMed  Google Scholar 

  13. Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol. 2011;104:391–6.

    Article  PubMed  Google Scholar 

  14. Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol. 2005;16:1061–8.

    Article  PubMed  CAS  Google Scholar 

  15. Deroose JP, Eggermont AM, Van Geel AN, et al. Long-term results of tumor necrosis factor α- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011;29:4036–44.

    Article  PubMed  CAS  Google Scholar 

  16. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra arterial cancer chemotherapy. Ann Surg. 1950;132:811–32.

    Article  PubMed  CAS  Google Scholar 

  17. Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion using an extracorporeal circuit. Ann Surg. 1958;148:616–32.

    Article  PubMed  Google Scholar 

  18. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremity. Surg Gyncol Obstet. 1969;129:305–8.

    Google Scholar 

  19. Cumberlin R, De Moss E, Lassus M, Friedman M. Isolated perfusion for malignant melanoma of the extremity: a review. J Clin Oncol. 1985;3:1022–31.

    PubMed  CAS  Google Scholar 

  20. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195–205.

    Article  PubMed  Google Scholar 

  21. Hegazy MA, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol. 2007;14:568–76.

    Article  PubMed  Google Scholar 

  22. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115:1932–40.

    Article  PubMed  CAS  Google Scholar 

  23. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213:306–18.

    Article  PubMed  Google Scholar 

  24. Huismans AM, Kroon HM, Kam PC, Thompson JF. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol. 2011;18:1877–83.

    Article  PubMed  Google Scholar 

  25. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009;16:2570–8.

    Article  PubMed  Google Scholar 

  26. Alexander HR, Fraker DL, Bartlet DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol. 2010;28:114–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA

    Joyce Wong MD & Jonathan S. Zager MD, FACS

  2. Department of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA

    Y. Ann Chen PhD & Kate J. Fisher MA

Authors
  1. Joyce Wong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Ann Chen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kate J. Fisher MA
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan S. Zager MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan S. Zager MD, FACS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, J., Chen, Y.A., Fisher, K.J. et al. Isolated Limb Infusion in a Series of Over 100 Infusions: A Single-Center Experience. Ann Surg Oncol 20, 1121–1127 (2013). https://doi.org/10.1245/s10434-012-2782-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2782-8

Keywords

Search

Navigation